Inovio Pharmaceuticals Inc (NYSEMKT:INO) Innovating The Unique Way
In 2013, there have been numerous medication-mortgage approvals from the U.S FDA. This has improved the stock price of many pharmaceutical companies. Inovio Pharmaceuticals Inc (NYSEMKT:INO) is one such company that has seen steady growth this year.
The company primarily focuses on the developing new-generation vaccines for medical conditions such as melanoma and other related attacks. INO has steadily introduced effective treatments that are in various stages of clinical study. One of its primary clinical candidates, the H7N9 DNA vaccine is currently under trial.
About the company
Inovio Pharmaceuticals Inc (NYSEMKT:INO) is involved in revolutionizing the development of various vaccines. These vaccines are used in the prevention and treatment of infectious diseases and cancers. Inovio is revolutionizing vaccines to prevent and treat today’s cancers and challenging infectious diseases. The company’s SynCon® vaccines are used in combination with the proprietary electro-poration delivery. These have been able to generate excellent immune responses.
The therapeutic T-cell responses have exceeded that of other technologies with reference to breadth, magnitude and the response rate. To date, data that has been collected from human research has shown that the safety profile is also very steady. Its lead candidate is currently in a Phase 2 trial study.
Partners in innovation
There are several other Phase I and pre-clinical programs that target lung, breast and prostate cancers as well as diseases such as malaria, hepatitis C, influenza and HIV. The company works with various collaborators and partners such as the University of Pennsylvania, HIV Vaccines Trial Network, NIH, Merck, U.S. Military HIV Research Program, National Cancer Institute, PATH Malaria Vaccine Initiative, University of Manitoba and the University of Southampton.
INO’s SynCon technology helps in the designing of universal-vaccines that are capable of providing different cross-protection against changing or existing pathogen-strains such as human immunodeficiency virus (HIV) and influenza. Its electroporation delivery technology utilizes brief, controlled electrical-pulses to help increase cellular-uptake of the vaccine.